The 2019-20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Adam J. Fein, Ph.D.
Drug Channels Institute

October 2019

Full report available at https://drugch.nl/wholesale
Copyright © 2019 by Pembroke Consulting, Inc., d/b/a Drug Channels Institute. All rights reserved.

This report is protected by copyright law and may not be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed, or resold, in whole or in part, in any form or manner or by any means whatsoever, by any person without prior written consent. This report may be cited in commercial documents with full and appropriate attribution. This report is for informational purposes only and is provided “as is” without any express or implied warranty. The analyses in this report are based solely on information and data that are in the public domain. All conclusions, findings, opinions, and recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations in this report or otherwise. Nothing in this report should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

Drug Channels® is a registered trademark of Pembroke Consulting, Inc.
LICENSE TERMS

This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.


The complete End User License Agreement is available at: https://drugch.nl/2019-20EULA

Please contact us at admin@drugchannels.net if you would like to upgrade the license at any time after purchase. You will pay only the difference in license fee.
ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the CEO of Drug Channels Institute (DCI), a leading management educator for and about the pharmaceutical industry. DCI is a subsidiary of Pembroke Consulting, Inc.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, The Washington Post, Forbes, and many others.

His popular and influential Drug Channels website is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. Drug Channels is the only place where you’ll find a serious discussion of PBMs, drug pricing, and pharmacy economics, all explained with humor and a healthy dose of pop culture.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and his undergraduate degree from Brandeis University. He lives in Philadelphia with his wife, Paula, and their two children.

Contact information
Adam J. Fein, Ph.D.
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.DrugChannelsInstitute.com
Email: afein@drugchannels.net

Visit Dr. Fein’s Drug Channels blog for the latest industry updates!

DRUG CHANNELS
Expert Insights on Pharmaceutical Economics and the Drug Distribution System
www.DrugChannels.net
ABOUT DRUG CHANNELS INSTITUTE

Drug Channels Institute (DCI) is a leading provider of specialized management education for and about the pharmaceutical industry.

Drug Channels Institute combines Dr. Fein’s expertise and cutting-edge analysis—such as this 2019-20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—into comprehensive, interactive e-learning modules that offer your team a thorough grounding in crucial industry topics. These online learning tools explain highly complex economic and business data and concepts so you can:

- Make better decisions to achieve your business goals
- Improve relationships with key accounts
- Understand your customers, channels, and the economics of the U.S. pharmaceutical industry

View a module list at http://drugchannelsinstitute.com/products/e-learning-modules/.

DCI can code and brand any module for your company’s internal Learning Management System. Or you can get started quickly by letting us host your team via our online e-learning portal. DCI’s hosted e-learning modules are instantly viewable on all computer platforms.

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700 x11
Website: www.drugchannelsinstitute.com
Email: paula@drugchannelsinstitute.com
Introduction and Guide to the 2019-20 Report

For pharmaceutical wholesalers, 2019 offered relative stability after a volatile and challenging period. The industry is confronting a diverse set of business, political, and legal challenges, some of which have persisted for years:

- Vertical and horizontal mergers and acquisitions are reshaping the pharmacy and PBM industries, leading to unprecedented consolidation and shakeout among wholesalers’ customer base. Wholesalers’ smaller pharmacy customers face mounting pressures on their prescription profits.

- Payers and PBMs are tightening their management of specialty drugs, pressuring such key wholesaler customer groups as independent specialty pharmacies, dispensing physician practices, and hospital pharmacies.

- List prices for brand-name drugs are growing at rates slower than historical norms. Deflation in generic drug prices continues, though the rate of change has steadied.

- After years of delay, a market for provider-administered biosimilars has begun to develop. Biosimilars’ adoption rates are growing, and their prices are declining.

- The federal government and multiple states are pursuing new policies aimed at introducing the commercial importation of drugs intended for foreign markets.

- Regulatory efforts to remove the role of rebates in the drug channel system failed. List prices remain a core component of intermediary compensation. The prospects for legislative action remain highly uncertain.

- Wholesalers have ceased major acquisition activity. The large wholesalers have collectively written down $6 billion for their unsuccessful diversification efforts: AmerisourceBergen for its compounding services, Cardinal Health for its medical products manufacturing, and McKesson for its international distribution and pharmacy businesses.

- Wholesalers’ potential financial liabilities for the opioid crisis are becoming clearer. However, their culpability for their role in the distribution of opioids is not known.

- Cell and gene therapies are poised to transform the treatment for many serious and previously untreatable conditions—and to create new channel models.

We project that U.S. drug distribution revenues for the Big Three public wholesalers—AmerisourceBergen, Cardinal Health, and McKesson—will reach $482 billion in 2019. However, gross margin for drug distribution will decline for the fifth consecutive year, though ongoing revenue growth will continue to moderate the reduction in gross profits.
Understanding an Evolving Channel

This 2019–20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—our 10th edition—is the most comprehensive, fact-based tool for understanding and analyzing the U.S. pharmaceutical distribution industry.

This definitive, nonpartisan resource thoroughly updates our annual exploration into the industry’s interactions with—and services for—other participants in our healthcare system. The report synthesizes a wealth of statistical data, research studies, financial information, and my own unique business consulting experience. It will aid pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospital executives, pharmacy buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and many others.

This 2019-20 edition contains the most current financial and industry data along with detailed information about the strategies and market positions of the largest companies: AmerisourceBergen, Cardinal Health, and McKesson. It updates our annual analysis of each wholesaler’s business segments and underlying business profitability, based upon our proprietary economic models. The information allows you to assess differences among the public wholesalers’ business organizations, strategies, and financial performance. Where appropriate, financial data have been restated based on new disclosures.

What’s New in the 2019-20 Report


New material in this 2019-20 edition includes:

- A new Section 5.7 examines the financial factors that determine executive compensation at each of the Big Three wholesalers.

- Chapter 6, which covers the forces of change facing drug distribution, has been expanded. Notable additions include:
  
  o The material in Section 6.1, which analyzes the pharmaceutical industry outlook, adds new material on wholesalers’ strategic reaction to these changes.

  o A new Section 6.2.5. discusses the potential impact of commercial importation of drugs intended for foreign markets.

  o A new Section 6.3.4. examines channel disruption for cell and gene therapies.

  o Our analysis of the biosimilar market in Section 6.4. includes new data that track adoption curves against four reference products.

- **Chapter 3** contains new data about the structure and operations of the hospital market.

- **Chapter 8** analyzes newly disclosed financial information about Cardinal Health’s business segments and its relationship with UnitedHealth Group’s OptumRx business.

- The report offers 19 more exhibits than last year’s edition.

**Structure of the 2019-20 Report**

*The 2019-20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors* analyzes the industry in a preface and three major sections, comprising nine total chapters.

**PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES** provides an integrated overview of the major themes that recur throughout our analysis. Each theme includes links to relevant chapters and sections within the full report.

**SECTION I: WHOLESALER AND CUSTOMER INDUSTRY ANALYSIS**

- **Chapter 1: Industry Overview** (page 8) defines the industry, describes business differences between full-line wholesaling and specialty distribution, summarizes wholesalers’ obligations under the Drug Supply Chain Security Act (DSCSA), explains wholesalers’ channel roles, and analyzes the products that wholesalers sell. It also identifies the major full-line wholesalers and specialty distributors, and it provides the latest data on their market share and revenues.

- **Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies** (page 29) analyzes the pharmacy market—the customer group that accounts for the majority of wholesalers’ revenues. It covers wholesalers’ services for smaller pharmacies, wholesalers’ participation in the pharmacy-PBM relationship via Pharmacy Services Administrative Organizations (PSAOs), and interactions with pharmacy buying groups.

  The chapter also analyzes how wholesalers work with larger pharmacies, including our updated analysis of the large generic sourcing consortia between wholesalers and the largest pharmacies. **Section 2.4,** (page 54) analyzes wholesalers’ role in the distribution of patient-administered drugs that specialty pharmacies dispense. We also consider wholesaler-owned specialty pharmacies.

- **Chapter 3: Channel Role for Physician Office/Clinics and Hospitals** (page 60) examines channels for provider-administered medications, explains the buy-and-bill system for drugs administered in outpatient settings, and describes the role and functions that wholesalers perform for hospitals, including hospitals that participate in the 340B Drug Pricing Program. This chapter also provides an in-depth consideration of group purchasing organizations (GPOs) for both hospitals and physician practices.
SECTION II: BUSINESS ECONOMICS AND INDUSTRY TRENDS

- **Chapter 4: Wholesaler Profitability** (page 92) delves into the industry’s income statement economics to explain the underlying sources of drug distribution profits. We deconstruct buy-side and sell-side gross margin components, distinguish sell-side profits from specialty and traditional drugs, and explain distribution service agreements (DSAs) with manufacturers. We analyze overall gross margins and operating profits, as well as wholesalers’ gross profits from brand-name vs. generic drugs. This chapter also explains how brand-name drug price inflation affects wholesalers’ profits.

- **Chapter 5: Financial Stability and Cash Management** (page 118) provides a detailed analysis of the key metrics that illustrate wholesalers’ overall financial health. These include capital structures, debt (leverage), balance sheet assets, cash flow, return on invested capital, and stock market valuation and performance. Chapter 5 includes a section—new for the 2019-20 edition—explains executive compensation at the Big Three wholesalers.

- **Chapter 6: Forces of Change for Drug Distribution** (page 136) updates our analysis of key industry trends that will impact the market structure and economics of the pharmaceutical wholesaling and specialty distribution industries. It presents the outlook for net prescription drug spending, brand-name and generic pricing, and reform of the drug channel system.

  Chapter 6 separately examines trends affecting pharmacy dispensing channels and buy-and-bill channels, including market, regulatory, and legislative issues. It also considers the current status and outlook for pharmacy-dispensed and provider-administered biosimilars.

SECTION III: BIG THREE WHOLESALE COMPANY PROFILES

In this section, we analyze the latest financial data and strategies of the largest public companies. Each chapter provides parallel examinations of the Big Three public wholesalers. We scrutinize each company’s business history, acquisitions and divestitures, business mix, profitability, largest customers, and company-specific business trends.

- **Chapter 7: AmerisourceBergen Corporation** (page 182)
- **Chapter 8: Cardinal Health** (Page 202)
- **Chapter 9: McKesson Corporation** (page 214)
How to Use the 2019-20 Report

The chapters are self-contained and do not need to be read in order. We include extensive internal references to help you navigate the entire document and customize it to your specific needs. After clicking a link, use the following shortcuts to return to your previous location in the document:

- Windows: ALT+Left Arrow
- Mac: Command+Left Arrow

We offer more than 450 endnotes, most of which have hyperlinks to original source materials. The report also includes a list of the Acronyms and Abbreviations (page 234) used within it.

To search the entire PDF document for every occurrence of a word or phrase, use the following keyboard shortcuts:

- Windows: Shift+CTRL+F
- Mac: Shift+Command+F

As always, I welcome your feedback. Please contact me if you have any questions or comments about The 2019-20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.

Adam J. Fein
October 2019

P.S. Click here for post-publication errata.
CONTENTS

PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES ................................................................. 1
SECTION I: WHOLESALER AND CUSTOMER INDUSTRY ANALYSIS .................................................... 7

Chapter 1: Industry Overview .............................................................................................................. 8
  1.1. Wholesale Industry Fundamentals .............................................................................................. 8
    1.1.1. Defining Drug Wholesale Distribution .................................................................................. 8
    1.1.2. Full-Line Wholesalers ........................................................................................................ 9
    1.1.3. Specialty Distributors ......................................................................................................... 11
    1.1.4. Regulation and Supply Chain Security ............................................................................... 13
  1.2. The Products That Wholesalers Sell ............................................................................................ 15
    1.2.1. Brand vs. Generic Drugs .................................................................................................... 15
    1.2.2. Route of Administration ................................................................................................... 16
    1.2.3. Traditional vs. Specialty Drugs ........................................................................................ 17
  1.3. Overview of Wholesalers’ Channel Roles ..................................................................................... 18
    1.3.1. Physical Distribution .......................................................................................................... 18
    1.3.2. Financial Intermediation .................................................................................................... 19
    1.3.3. Services for Pharmacies, Providers, and Manufacturers .................................................. 20
    1.3.4. Impact on Pharmacy and Provider Reimbursement .......................................................... 21
  1.4. Industry Participants .................................................................................................................... 22
    1.4.1. Big Three Wholesalers: Revenue and Growth Trends ....................................................... 22
    1.4.2. Specialty Product Distribution Market Share .................................................................... 24
    1.4.3. Other Wholesale Market Participants .............................................................................. 26

Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies .................................................. 29
  2.1. The Pharmacy Market .................................................................................................................. 30
    2.1.1. Outpatient Dispensing Formats .......................................................................................... 30
    2.1.2. Pharmacy Market Size and Structure .............................................................................. 32
  2.2. Independent Pharmacies ............................................................................................................ 33
    2.2.1. Industry Position and Wholesaler Market Shares ............................................................... 34
    2.2.2. Wholesaler Services for Independent Pharmacies ........................................................... 37
    2.2.3. Franchise Programs and Marketing Groups ........................................................................ 39
    2.2.4. PSAOs and the Wholesalers’ Role in the Pharmacy-PBM Relationship ............................ 40
    2.2.5. Pharmacy Group Purchasing Organizations and Wholesaler Relationships .................. 44
Chapter 5: Financial Stability and Cash Management

5.1. Debt, Coverage, and Liquidity Ratios ................................................................. 118
5.2. Balance Sheet Assets ......................................................................................... 118
5.3. Cash Conversion Cycle ....................................................................................... 118
  5.3.1. Inventory Levels and Days Inventory Outstanding ........................................ 121
  5.3.2. Accounts Receivable and Days Sales Outstanding ....................................... 121
  5.3.3. Accounts Payable and Days Payable Outstanding ....................................... 121
5.4. Uses of Cash ........................................................................................................ 122
5.5. Return on Invested Capital ................................................................................. 122
5.6. Stock Market Performance .................................................................................. 122
5.7. Executive Compensation ...................................................................................... 122

Chapter 6: Forces of Change for Drug Distribution .................................................... 136

6.1. The Outlook to 2023 .......................................................................................... 136
  6.1.1. The Outlook for U.S. Pharmaceutical Purchases and Wholesaler Revenues .. 136
  6.1.2. The Outlook for Brand-Name Drug Prices and Wholesaler Responses ......... 136

9.4. Growth Trends .................................................................................................................. 226
9.4.2. McKesson Specialty Health......................................................................................... 228
9.4.3. McKesson Europe...................................................................................................... 228
9.4.4. McKesson Canada....................................................................................................... 231
Acronyms and Abbreviations ............................................................................................... 234
Endnotes .................................................................................................................................. 235
LIST OF EXHIBITS

Exhibit 1: Full-Line Wholesale Revenues, by Type of Customer, 2017 ................................................................. 9
Exhibit 2: Full-Line Wholesalers, Inventory Levels vs. Product Sales, by Product Type, 2017................................. 10
Exhibit 3: Full-Line Wholesalers, Inventory Levels and Product Sales, by Product Type, 2011 vs. 2017 .......... 10
Exhibit 4: Specialty Distributor Revenues, by Customer Type, 2017 .................................................................... 11
Exhibit 5: Specialty Distributor Sales, by Therapeutic Area, 2017 ........................................................................ 12
Exhibit 6: Distribution Center Operational Metrics, Full-Line Wholesalers vs. Specialty Distributors, 2017 .... 12
Exhibit 7: Timeline of DSCSA Requirements for Wholesale Distributors, 2013 to 2023 ................................. 13
Exhibit 8: Unbranded and Branded Generics, Share of U.S. Prescriptions, 2002 to 2023 ................................. 16
Exhibit 10: U.S. Drug Distribution and Related Revenues at Big Three Wholesalers, Calendar Year 2018 ...... 22
Exhibit 13: Specialty Product Distribution Revenues, by Division and Parent Company, 2018 ..................... 25
Exhibit 14: The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs ................................................................................................ 29
Exhibit 15: Total U.S. Pharmacy Industry Revenues, Prescriptions, and Locations, by Dispensing Format, 2018 ........................................................................................................................................ 32
Exhibit 16: Number of Independent Pharmacy Locations, 2001 to 2018 ......................................................... 34
Exhibit 17: Independent Pharmacies, Average Per-Prescription Gross Profits and Margins, 2013 to 2017 ...... 36
Exhibit 18: Estimated Drug Sales and Market Share With Independent Pharmacies, by Wholesaler, 2018 ..... 36
Exhibit 19: U.S. Pharmacy Franchise and Marketing Programs, 2019 ............................................................. 39
Exhibit 20: Customer Satisfaction With Pharmacies, by Dispensing Format and Company, 2019 ............... 40
Exhibit 21: Largest Pharmacy Services Administrative Organizations, by Members and Ownership, 2019 .... 43
Exhibit 22: Pharmacy Buying Groups and Primary/Preferred Wholesaler Relationships, by Number of Pharmacies, 2019 ...................................................................................................................................... 45
Exhibit 23: Wholesaler Generic Source Programs, Number of SKUs and Manufacturers, 2011 to 2017 ....... 47
Exhibit 24: Largest U.S. Pharmacies and Their Primary Wholesale Suppliers, 2019 ............................................. 48
Exhibit 25: Alignment Between the Big Three Wholesalers and the Top Five Pharmacy Companies ............. 49
Exhibit 26: Full-Line Wholesaler Sales to Retail Chain Warehouses, 2008 to 2018 ........................................... 50
Exhibit 27: Share of U.S. Generic Purchasing Volume, by Organization, 2019 ..................................................... 51
Exhibit 28: Specialty Drug Prescription Revenues, by Dispensing Format, 2018 ............................................. 55
Exhibit 29: Prescription Revenues and Market Share from Specialty Pharmaceuticals, by Company, 2018 .... 55
Exhibit 30: Alternative Channels to Specialty Pharmacies in Limited Dispensing Networks ....................... 58
Exhibit 31: Medical Benefit Spending on Provider-Administered Drugs, by Drug Category and Payer, 2017 .. 61
Exhibit 32: Medical Benefit Spending for Outpatient Medical Benefit Drugs, by Site of Care and Payer, 2017 61
Exhibit 33: Medicare Part B, Share of Spending, by Site of Care and Drug, 2017 ................................. 62
Exhibit 34: Commercial Medical Benefit Claims for Outpatient Provider-Administered Drugs, by Site of Care and Therapy Class, 2015 ................................................................. 63
Exhibit 35: Buy-and-Bill System for Distribution and Reimbursement of Provider-Administered Outpatient Drugs ........................................................................................................... 63
Exhibit 36: Primary Roles of Third-Party Payer, Distributor, and Provider in Buy-and-Bill System .............. 64
Exhibit 37: Chargebacks As a Percentage of Net Sales, Full-Line Wholesalers, 2009 to 2017 ................ 66
Exhibit 38: Reimbursement Method for Provider-Administered Drugs Paid Under the Commercial Medical Benefit, by Site of Care, 2017 ................................................................. 69
Exhibit 39: Commercial Medical Benefit Cost Per Claim for Outpatient Specialty Drugs, by Site of Care, 2017 70
Exhibit 40: Patient Cost Sharing for Provider-Administered Drugs ....................................................... 72
Exhibit 41: Most Important Service Offered by Community Practice GPOs ........................................... 75
Exhibit 42: Specialty Physician Practice GPOs and Ownership, 2019 ....................................................... 75
Exhibit 43: Percentage of Oncology Practices With In-Practice Oral Oncology Drug Dispensing, 2013 to 2018 78
Exhibit 44: Patient-Administered Oncology Volume, by Dispensing Channel, 2018 .............................. 78
Exhibit 45: U.S. Hospitals, by Type and Ownership, 2017 ................................................................. 80
Exhibit 46: Share of Community Hospitals, by Health System Affiliation, 2001 to 2017 ...................... 81
Exhibit 47: Ten Largest Integrated Delivery Networks, by Number and Type of Facilities, 2019 .............. 81
Exhibit 48: Hospital Costs, by Type of Expense, 2016 ........................................................................ 82
Exhibit 49: Prescription Drug Costs As a Percentage of Hospital Expenses, 2006 to 2016 .................. 82
Exhibit 50: Hospital Pharmaceutical Expenses per Staffed Bed, by Ownership and IDN Affiliation, 2018 . 83
Exhibit 51: Ten Hospitals With Largest Pharmacy Spending, 2017 .................................................... 83
Exhibit 52: Inpatient Pharmacist and Pharmacy Technician Employment, by Number of Staffed Beds, 2017 . 84
Exhibit 53: Largest Group Purchasing Organizations, by Total Purchasing Volume, 2019 .................... 85
Exhibit 54: Hospitals With a Specialty Pharmacy, by Number of Staffed Beds, 2016 vs. 2018 ............. 87
Exhibit 55: Key Elements on a Wholesaler Income Statement ............................................................. 92
Exhibit 56: Sources of a Wholesaler’s Gross Margin from Brand-Name Drugs ...................................... 93
Exhibit 58: U.S. Drug Distribution Gross Profits, Big Three Wholesalers, Total and Annual Change, 2015 to 2019 ........................................................................................................ 103
Exhibit 59: Estimated Buy-Side and Sell-Side Contributions to Wholesalers’ Gross Margin, 2019 ........ 104
Exhibit 60: Estimated Drug Distribution Gross Margin, Brand-Name vs. Generic Drugs, 2019 .......... 105
Exhibit 61: Big Three Wholesalers, Revenues and Gross Profits, Brand vs. Generic Drugs, 2019 ........... 106
Exhibit 62: Path of Wholesaler Gross Profits, Brand vs. Multi-Source Generic Drug, 2019 ............... 107
Exhibit 63: Median Sell-Side Discount for Generic Drugs Sold to Retail Pharmacies, by Number of Manufacturers, 2015 vs. 2019 ........................................................................ 109
Exhibit 126: McKesson, Distribution Businesses, Gross and Segment Operating Profitability Metrics, 2016 to 2019 ........................................................................................................................................219
Exhibit 127: McKesson, Estimated Revenues and Operating Profit, by Segment, FY2019.........................220
Exhibit 129: McKesson, Revenues from CVS Health, 2015 to 2019................................................................223
Exhibit 130: McKesson, Days Sales Outstanding from CVS Health vs. All Other Customers, 2015 to 2019 ......225
Exhibit 131: McKesson, Revenues from Rite Aid, 2015 to 2019 ..................................................................226
Exhibit 133: McKesson Health Mart, Store Count, 2007 to 2019 ..............................................................227
Exhibit 134: McKesson Europe, Revenues and Profit, by Operating Segment, 2019 .................................229
Exhibit 135: Celesio, Revenues, by Operating Segment, 2016 to 2019 .........................................................230
Exhibit 136: McKesson Canada, Revenues and Growth, 2015 to 2019 .......................................................232